Gainers
- Sera Prognostics SERA stock increased by 231.9% to $6.97 during Wednesday's regular session. The market value of their outstanding shares is at $218.4 million.
- Phio Pharma PHIO shares increased by 60.36% to $1.8. The company's market cap stands at $4.3 million.
- Syros Pharmaceuticals SYRS stock moved upwards by 45.03% to $4.09. The market value of their outstanding shares is at $86.1 million.
- Altimmune ALT shares rose 39.94% to $7.24. The market value of their outstanding shares is at $388.7 million.
- Arvinas ARVN shares increased by 30.94% to $30.34. The market value of their outstanding shares is at $1.6 billion.
- Altamira Therapeutics CYTO shares increased by 29.69% to $0.47. The market value of their outstanding shares is at $3.7 million.
Losers
- OptiNose OPTN stock declined by 22.4% to $1.14 during Wednesday's regular session. The company's market cap stands at $128.0 million.
- Mira Pharmaceuticals MIRA stock declined by 21.92% to $2.28. The company's market cap stands at $33.7 million.
- InVivo Therapeutics Hldg NVIV shares decreased by 18.71% to $0.72. The market value of their outstanding shares is at $2.2 million.
- Allarity Therapeutics ALLR shares decreased by 18.24% to $0.47. The company's market cap stands at $2.2 million.
- GlucoTrack GCTK shares fell 17.07% to $0.26. The market value of their outstanding shares is at $5.3 million.
- Sonoma Pharmaceuticals SNOA stock declined by 14.94% to $0.19. The company's market cap stands at $2.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ALTAltimmune Inc
$8.402.69%
ARVNArvinas Inc
$18.483.65%
CYTO
$0.2620-12.7%
GCTKGlucoTrack Inc
$0.269821.7%
MIRAMira Pharmaceuticals Inc
$1.098.98%
OPTNOptiNose Inc
$0.43813.82%
PHIOPhio Pharmaceuticals Corp
$1.66-4.59%
SERASera Prognostics Inc
$8.788.00%
SNOASonoma Pharmaceuticals Inc
$2.48-2.75%
SYRSSyros Pharmaceuticals Inc
$0.20692.53%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in